Verve Therapeutics, Inc. announced that on August 3, 2022, John Evans notified the Chairman of the Company's Board of Directors of his decision to resign, effective August 4, 2022, from his position as a member of the Board. Mr. Evans' resignation did not result from any disagreements with management or the Board. Mr. Evans was a Class I director of the Company.

On August 5, 2022, the Board, following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Lonnel Coats as a member of the Board and as a member of the Audit Committee of the Board, effective as of August 8, 2022. Mr. Coats was designated as a Class I director with a term expiring at the 2025 annual meeting of the stockholders of the Company and thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined that Mr. Coats is “independent” as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations.

Mr. Coats, age 58, has served as Chief Executive Officer and Director of Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, since July 2014., and previously served as Lexicon's President and Chief Executive Officer from July 2014 to October 2021. From 1996 through June 2014, Mr. Coats served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo-based Eisai Co. Ltd., a Japanese pharmaceutical company, including as Chief Executive Officer of Eisai Inc. from 2010 to June 2014 and as President and Chief Operating Officer of Eisai Inc. from 2004 to 2010.

As President and Chief Executive Officer of Eisai, Mr. Coats oversaw the commercialization of Eisai products in the therapeutic areas of oncology, neurology, GI, epilepsy and metabolic disorders. He also led the diversification of Eisai's business through over $5 billion in strategic acquisitions, licensing and partnerships, which included the acquisition of MGI Pharma in 2008 and the licensing of Belviq in 2011. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions.

Mr. Coats has served on the board of Blueprint Medicines Corporation, a global precision therapy company, since February 2016. Mr. Coats received his Bachelor of Science in public administration from Oakland University.